Shots:
- Sanofi to acquire Blueprint Medicines, expanding its rare immunological disease portfolio
- As per the deal, Blueprint shareholders will receive $129/share in cash (~$9.1B equity value) & one non-tradeable CVR of $2 & $4 per share upon achievement of development & regulatory milestones, respectively, for BLU-808, totaling the deal value up to $9.5B on a fully diluted basis; closing expected in Q3’25
- Acquisition incl. FDA & EC-approved Ayvakit/Ayvakyt (avapritinib) for ASM & ISM as well as elenestinib, a KIT D816V inhibitor in P-II/III (HARBOR) trial for ISM & smoldering SM, with BLU-808, an oral wild-type KIT inhibitor
Ref: PRNewswire | Image: Blueprint Medicines| Press Release
Related News:- Regeneron and Sanofi Report P-III (AERIFY-1 & AERIFY-2) Trials Data of Itepekimab for Chronic Obstructive Pulmonary Disease (COPD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
